Moderna, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Moderna, Inc. (MRNA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value of $153.00 million as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue · last filed 2026-02-20
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $153.00M.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $359.00M.
- 2023-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $1.44B.
- 2022-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value $3.48B.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value as first filed |
|---|---|---|
| 2025-12-31 | $153.00M 10-K · filed 2026-02-20 | |
| 2024-12-31 | $359.00M 10-K · filed 2026-02-20 | |
| 2023-12-31 | $1.44B 10-K · filed 2025-02-21 | |
| 2022-12-31 | $3.48B 10-K · filed 2024-02-23 | |
| 2021-12-31 | $6.25B 10-K · filed 2023-02-24 | |
| 2021-09-30 | $10.36B 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $6.55B 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $3.65B 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $2.98B 10-K · filed 2022-02-25 | $2.98B 10-K · filed 2021-02-26 |
| 2020-09-30 | $2.02B 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $1.93B 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $669.83M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $286.31M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $201.01M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $181.37M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $412.48M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $220.43M 10-K · filed 2020-02-27 | |
| 2017-12-31 | $130.59M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |